ApicHope Pharmaceutical Co Ltd (300723)

Currency in CNY
74.90
+2.83(+3.93%)
Closed·

300723 Financial Summary

Key Ratios

P/E Ratio-27.72
Price/Book8.36
Debt / Equity125.98%
Return on Equity-26%
Dividend Yield0.00%
EBITDA-115.53M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2023
01/01
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -1.29%
Dividend Yield
-
Industry Median 1.53%
Annualised payout
-
Paid annually
5-Years Growth
-
Growth Streak

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 40.26
(-46.25% Downside)

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
0.13 / --
Revenue / Forecast
376.96M / --
EPS Revisions
Last 90 days

FAQ

What were ApicHope Pharmaceutical's earnings for the latest quarter?

The ApicHope Pharmaceutical EPS (TTM) is -1.29. ApicHope Pharmaceutical reported sales of 376.96, net income of 56.59, and EPS of 0.13 for the latest quarter.

What was ApicHope Pharmaceutical's net income for the latest quarter?

ApicHope Pharmaceutical's net income for the latest quarter was 56.59.

How did ApicHope Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 210.41 in the previous quarter to 376.96 in the latest quarter, and net income moved from -293.50 to 56.59 compared to the previous quarter.

What is ApicHope Pharmaceutical's net profit margin on a TTM basis?

ApicHope Pharmaceutical's trailing twelve months (TTM) net profit margin is -37.24%.

How does ApicHope Pharmaceutical's debt to equity ratio compare to industry standards?

ApicHope Pharmaceutical's total debt-to-equity ratio is 125.98%.

What is ApicHope Pharmaceutical's return on investment on a TTM basis?

ApicHope Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is -26.00%.

Did ApicHope Pharmaceutical gain or lose cash last quarter?

In the latest quarter, ApicHope Pharmaceutical's net change in cash was 200.42 million.

What were ApicHope Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, ApicHope Pharmaceutical reported total assets of 5,245.75 million and total liabilities of 1,860.24 million.

How has ApicHope Pharmaceutical's total revenue grown this year?

ApicHope Pharmaceutical's total revenue was 210.41 in the previous quarter and 376.96 in the latest quarter.

What is ApicHope Pharmaceutical's gross margin on a TTM basis?

ApicHope Pharmaceutical's trailing twelve months (TTM) gross margin is 52.49%.

What was ApicHope Pharmaceutical's revenue per share for the latest quarter?

ApicHope Pharmaceutical's revenue per share for the latest quarter was 7.07.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.